Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (NASDAQ: CADX) concerning the proposed acquisition of the Company by Mallinckrodt plc (“Mallinckrodt”) (NYSE: MNK). Under the terms of the definitive merger agreement, Cadence stockholders will receive $14.00 in cash for each share of Cadence owned, valuing the transaction at approximately $1.3 billion on a fully diluted basis.
The investigation concerns whether the Cadence Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values Cadence’s common stock.
If you are a Cadence stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.